Sozol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sozol

What Type of Medicine is Sozol and Its Core Composition?

Sozol is a pharmaceutical preparation classified as a Proton Pump Inhibitor (PPI). It belongs to the category of antisecretory drugs used to manage the production of acid within the stomach. The active chemical component is Pantoprazole, a synthetic substituted benzimidazole compound. This medication is a single-ingredient product, containing the substance as Pantoprazole sodium sesquihydrate.

The core action involves the selective targeting and irreversible binding to the final step in the acid-secretion pathway: the H+/K+-ATPase enzyme system, or proton pump. This specific mechanism provides a potent and sustained suppression of gastric acid secretion.

What is the General Purpose of Sozol?

The general purpose of this medicine is to achieve a significant, long-lasting reduction in the stomach’s overall acid environment. By limiting acid production, Sozol provides relief from discomfort associated with high acidity and facilitates the healing of irritated tissues. The PPI class is used to reduce gastric acidity across various patient groups. A typical application includes mitigating symptoms of chronic heartburn, where reducing acid exposure is essential for symptom management.

Available Forms: Sozol as a Delayed-Release Preparation

Sozol is most frequently supplied as a delayed-release oral tablet, a pharmaceutical preparation designed for optimal delivery. The tablet features an enteric coating, which protects the acid-sensitive Pantoprazole from degradation as it passes through the stomach's acidic environment. The compound is subsequently absorbed and activated in the small intestine, enabling targeted action. For situations where oral ingestion is not possible, Pantoprazole is also available for intravenous (IV) administration as a solution or powder for injection, providing an alternative route of administration.

What side effects are possible with Sozol?

Possible Side Effects and Safety Information

The safety profile of Sozol (Pantoprazole) is structured according to standardized regulatory categories detailing the frequency and system-organ class affected by adverse reactions. The medicine is contraindicated in individuals with known hypersensitivity to the formulation components or other substituted benzimidazoles.


Frequency-Classified Adverse Reactions

Adverse reactions are officially categorized based on incidence in clinical trials and post-marketing data:

  • Common Reactions: These frequently documented effects typically include headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, and dizziness.
  • Uncommon Reactions: Less frequent effects noted in regulatory labels include insomnia, rash, and fatigue. Severe, rare events include those affecting blood cell counts and severe hypersensitivity events.

Serious and Duration-Related Safety Patterns

Regulatory documents highlight rare but clinically important reactions and risks associated with exposure duration:

  • Serious Adverse Reactions: The label documents rare events such as Severe Hypersensitivity Reactions (e.g., Anaphylaxis), Acute Interstitial Nephritis, and certain Severe Cutaneous Adverse Reactions (SCARs).
  • Long-Term Use Concerns: Use for a year or longer is officially associated with potential risks including an increased incidence of bone fractures (hip, wrist, spine), Hypomagnesemia (low blood magnesium levels), and Vitamin B12 deficiency.

Population-Specific Notes

The official safety information includes specific considerations for certain patient groups. Different common side effects, such as fever and URI, are documented for pediatric patients. Furthermore, caution and monitoring are noted for patients with severe hepatic impairment.

Overdose and Emergency Response

The official regulatory documentation on Pantoprazole (Sozol) overdose indicates that clinical experience with very high dose levels, specifically those greater than 240 mg, is limited. Reported symptoms from spontaneous post-marketing cases are generally within the medicine’s known safety profile, primarily involving mild effects on the gastrointestinal and nervous systems. Documented manifestations may include headache, nausea, abdominal pain, diarrhea, vomiting, flatulence, and dizziness.

If an overdosage occurs, treatment must be symptomatic and supportive. The prescribing information clarifies that the drug is not removed by hemodialysis, meaning no specific antidote or forced removal procedure is known to be effective. The official overdose statements do not explicitly detail distinct manifestations or severity for specific patient populations.

When to Seek Immediate Help

According to government health authority guidance, individuals must seek immediate medical attention and contact emergency services if critical, life-threatening signs are present. Immediate action is required if the person has collapsed, experienced a seizure, is exhibiting trouble breathing, or cannot be awakened. It is also mandated to call the poison control helpline for specific guidance in an overdose situation.

Therapeutic Uses of Sozol

Quick Facts

  • Support for Reflux Disease: May assist in the healing and symptomatic management of erosive esophagitis, a tissue damage associated with gastroesophageal reflux disease (GERD).
  • Ulcer Management: Used in the treatment and support of healing for duodenal and gastric ulcers.
  • Rare Acid Conditions: Utilized in the long-term management of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
  • Ulcer Prevention: May be used to prevent the formation of gastroduodenal lesions (ulcers) that can be associated with the continuous use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

What Sozol Treats: Main Uses and Benefits

Sozol is a prescribed medication employed for conditions where a reduction in stomach acid production is therapeutically appropriate. Its primary function is to support the management and healing of acid-related damage within the gastrointestinal system.

The medication is indicated for the short-term treatment of erosive esophagitis, which involves injury to the esophagus caused by acid backflow associated with gastroesophageal reflux disease (GERD). It also supports the maintenance of healing for this condition, assisting in the sustained reduction of tissue damage.

Furthermore, Sozol is used to manage and promote the healing of ulcers that may develop in the stomach (gastric ulcers) and the upper part of the small intestine (duodenal ulcers). It is also an option for managing the rare, long-term condition known as Zollinger-Ellison syndrome, which is characterized by the stomach producing excessive acid. Additionally, the medicine may be prescribed to assist in the prevention of certain ulcers that may be associated with the required use of NSAIDs.

Eligibility and Restrictions for Use

Who Can and Cannot Use Sozol?

The eligibility for Sozol is strictly defined by regulatory authorities based on population safety and health status.

Contraindicated Populations

You must not use Sozol if you have a known hypersensitivity to Pantoprazole, any of its inactive components, or to medicines belonging to the substituted benzimidazole class. Use is also contraindicated if you are concurrently taking certain HIV antiviral medicines, including rilpivirine, atazanavir, or nelfinavir, due to the risk of reduced antiviral effectiveness.

Population Eligibility Rules

Population Group Eligibility Status
Adults Eligible for all approved uses.
Children (Oral Form) Approved for those 5 years of age and older for short-term treatment. Safety is not established beyond 8 weeks of treatment or in children younger than 5.
Children (IV Form) Approved for those 3 months of age and older.
Older Adults Eligible; no dosage adjustment required based on age alone.

Condition-Based Restrictions

Use requires special caution and pre-screening in certain circumstances. The presence of gastric malignancy must be excluded prior to starting Sozol therapy, as symptomatic relief may delay diagnosis. Patients with severe hepatic impairment require regular monitoring of liver enzymes. For patients with renal impairment, no dose adjustment is necessary. Use during pregnancy is conditional; it is reserved for when the potential benefit outweighs the risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Sozol (Pantoprazole), strictly according to regulatory labels. The interaction profile is primarily defined by two main mechanisms: the drug’s profound ability to suppress gastric acid and its metabolism through the CYP enzyme system.

Pharmacodynamic Interactions

Sozol's sustained elevation of gastric pH can reduce the absorption and bioavailability of co-administered medicines that require an acidic environment for uptake. This includes antifungals, such as Ketoconazole and Itraconazole, and certain antiretroviral agents (e.g., Atazanavir), potentially leading to a loss of therapeutic effect for those medicines. Co-administration with Clopidogrel may also reduce its antiplatelet effect.

Pharmacokinetic Interactions

Interactions involving the CYP enzyme system can alter the concentration of co-administered drugs. Co-administration with Warfarin or coumarin anticoagulants has resulted in increased International Normalized Ratio (INR) and prolonged prothrombin time (PT). For patients on high-dose Methotrexate therapy, co-administration may increase and prolong serum concentrations of methotrexate, potentially increasing toxicity. Separately, enzyme inducers like Rifampicin or the herbal product St. John's Wort can reduce the plasma concentration of Pantoprazole.

Mechanism of Action

The mechanism of action for Sozol (Pantoprazole) involves selective targeting of the final step of acid production within the stomach. The drug functions as a prodrug that is activated solely within the acidic environment of the secretory canaliculi of the gastric parietal cells, localizing its chemical activity. Its active form then acts as an irreversible covalent inhibitor of the H^+/K^+-ATPase enzyme system, or Proton Pump. By forming a stable disulfide bond with specific cysteine residues, the drug permanently disables the enzyme unit responsible for the exchange of hydrogen ions. This molecular action initiates a cascade that results in the prolonged reduction of gastric hydrochloric acid secretion. Since the inhibition is permanent, the drug blocks the acid-producing pathway independently of the upstream stimuli (like histamine or gastrin). The physiological consequence is a long-lasting elevation of intragastric pH. A core mechanistic feature is that the drug can only bind to the pumps that are actively secreting acid, which necessitates repeated administration to progressively inhibit the entire cycling pump population over time.

Dosage and Administration Information

How to use Sozol: Official Administration Guidelines

Sozol is available for administration by both the oral route as delayed-release tablets or an oral suspension, and via intravenous (IV) injection when oral intake is not feasible. The oral delayed-release tablets can be taken with or without food. However, the oral suspension must be administered approximately 30 minutes prior to a meal to ensure proper action.

The standard adult dosing regimen for many approved uses is 40 mg once daily. For conditions like Zollinger-Ellison Syndrome (ZES), initial oral dosing is 40 mg twice daily, with the possibility of doses being adjusted based on acid output measurements, sometimes requiring up to a studied 240 mg total daily dose. The IV administration is typically 40 mg once daily but is strictly limited to a 7 to 10 day course before transition back to oral therapy. The official instructions mandate that the IV administration must be discontinued immediately once the patient can tolerate oral intake.

Procedural constraints are mandatory: the delayed-release tablets and granules must not be crushed, split, or chewed to preserve the formulation's enteric coating. Furthermore, specific dose modification is required for certain populations; for instance, the daily dose should not exceed 20 mg in patients with severe hepatic impairment. If a dose is missed, the standard protocol is to take the next scheduled dose at the regular time, without doubling the dose.

Recent Clinical Evidence

Sozol: Recent Clinical Evidence

Research Evidence for Healing and Maintenance of Erosive Esophagitis

Randomized Controlled Trials (RCTs) were the primary design used in research that examined outcomes for adults and other populations diagnosed with erosive esophagitis (EE). These studies explored changes measured during the treatment period, typically lasting 4 to 8 weeks. Researchers monitored endoscopic healing rates—meaning they checked to see how tissue damage in the esophagus evolved—along with patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies regarding the measured changes in the integrity of the esophageal lining. For maintenance of healing, studies monitored whether symptoms recurred and if the healed tissue remained intact over longer intervals. Data show patterns related to the incidence of lesion recurrence in observed populations over periods of up to 12 months. Evidence is limited for maintenance outcomes extending beyond one year.

Research Evidence for Managing Gastric and Duodenal Ulcers

Sozol was studied in research that examined ulcer outcomes, which is a condition involving periods of heightened symptoms and physical discomfort. The studies primarily consisted of short-term RCTs focusing on adults diagnosed with ulcers in the stomach (gastric) or upper small intestine (duodenal). Research examined the measurement of ulcer closure rates using endoscopic confirmation as a primary outcome. Studies also monitored the evolution of symptoms and patient-reported experiences. Findings describe patterns observed in these studies regarding the measured status of ulcer closure within the 4 to 8 week timeframe. Many trials examining ulcer outcomes were conducted in a context where the treatment was combined with antibiotics for H. pylori eradication.

Evidence in Specific Patient Populations

Research has explored outcomes for Sozol in certain specific populations. Pediatric patients (children aged 5 years and older) with EE were evaluated in studies assessing short-term symptom changes and healing rates. The evidence base also includes observations related to older adults requiring long-term NSAID therapy. Subgroup findings examining comorbidity groups or pregnant populations rely on evidence that is considered insufficient or limited, meaning the results apply only to the specific populations studied.

Frequently Asked Questions (FAQ)

Common questions about Sozol (FAQ)


Q: How long does it typically take before Sozol starts working?

According to official product information, symptomatic relief may start about one day after beginning treatment. However, it may take a few days of consistent use to achieve maximal effect or improvement in symptoms. For certain conditions, the full course of treatment is necessary to reach the maximum benefit described in regulatory studies.


Q: Can I take Sozol if I am already taking supplements?

Official labels indicate that Sozol reduces stomach acid, which can affect the absorption of certain substances. This includes some herbal products, such as St. John's Wort, which regulatory documents advise avoiding. Official labels recommend informing a healthcare provider about all current supplements and vitamins.


Q: What is the risk of stopping Sozol suddenly?

Stopping the medication, especially after long-term use, may be associated with increased gastrointestinal symptoms, such as heartburn or dyspepsia. To limit this effect, some clinical guidelines recommend a gradual reduction (tapering) of the dose before completely discontinuing treatment. Changes to the treatment schedule are typically managed in consultation with a prescribing physician.


Q: Why does the official information list so many potential interactions?

Regulatory information explains that Sozol has two main pathways for potential interactions. First, its strong reduction of stomach acid can change how other medicines are absorbed. Second, Sozol is metabolized (broken down) in the liver by specific enzyme systems (CYP), which may alter the concentration of other drugs that use the same pathway.


Q: If I feel better, do I still need to finish the full course of Sozol?

Official guidance states that treatment may sometimes be discontinued once complete symptom relief has occurred, particularly for short-term uses. The decision to stop is typically managed in consultation with a healthcare provider. Official guidance suggests continuing the full prescribed course unless specific medical advice is received to discontinue it early.


Q: Is Sozol available over the counter?

The active ingredient, Pantoprazole, is available both as a prescription medicine and, in some locations, in lower doses (such as 20 mg) for non-prescription (over-the-counter) use. The availability of non-prescription forms is typically for the short-term treatment of frequent heartburn. The specific form and strength are determined by local regulatory approval and medical guidance.


Q: Is there a generic version of Sozol available?

The active component of Sozol is Pantoprazole. Official drug listings confirm that Pantoprazole is widely manufactured and available from various companies as a generic medicine, once the brand-name patent has expired.


Q: What should I do if the side effects of Sozol bother me?

Official patient information suggests contacting a healthcare provider if side effects are severe or persistent. Patients are generally advised to seek medical attention if they experience any symptoms listed as serious adverse reactions in the regulatory documentation.


Q: Can taking Sozol affect my ability to drive or operate machinery?

If side effects such as fatigue, dizziness, or visual disturbances occur, official warnings state that your ability to drive or operate complex machinery may be impaired. If these effects are experienced, regulatory information cautions against driving or operating machinery until the symptoms have resolved.


Q: What is the half-life of Sozol, and what does that mean?

Pharmacokinetic data from regulatory documents show that the elimination half-life of Pantoprazole is about one hour. This short half-life does not reflect the drug's long duration of action. The therapeutic effect lasts longer because the drug permanently binds to and disables the acid pumps.


Q: Does Sozol interact with common pain relievers like ibuprofen?

Official labels do not list a direct chemical interaction between Pantoprazole and common pain relievers like ibuprofen. Sozol is sometimes prescribed alongside nonsteroidal anti-inflammatory drugs (NSAIDs) to help protect against the gastrointestinal side effects that NSAIDs can cause.


Q: What is the legal classification of Sozol (e.g., Prescription-only)?

Based on official documentation, Sozol is classified as both a prescription-only medicine and, at specific lower doses, a non-prescription medicine. The availability and legal status depend on the jurisdiction and the dose prescribed or purchased.


Q: How long does the effect of Sozol last after the last use?

The acid-reducing effect of Sozol lasts for more than 24 hours. This is because the drug works by permanently inhibiting the acid pumps in the stomach. Full acid production will only resume once the body generates new proton pumps.


Q: What is the ingredient list for Sozol besides the active substance?

The official product information, such as the Summary of Product Characteristics, includes a complete list of all inactive ingredients (known as excipients). This list is made available for patients to review in case of any known allergies or sensitivities to non-active components.


Q: Is there an official patient information leaflet for Sozol online?

Yes, government agencies and regulatory authorities, including the FDA and the NIH, provide official patient information leaflets or medication guides for Pantoprazole. These resources are available online for public access and are considered the definitive source of patient information.


Q: Does Sozol interfere with birth control pills?

Studies reviewed by regulatory bodies indicate that Pantoprazole does not appear to affect the efficacy or concentration of hormonal contraceptives. This includes birth control pills containing common active ingredients like levonorgestrel and ethinyl estradiol.


Q: What happens if I accidentally take two doses of Sozol?

Official guidance warns against taking a double dose to compensate for one that was missed. Regulatory authorities recommend contacting a Poison Control Center or seeking medical advice if a patient accidentally takes two doses or suspects an overdose.


Q: Can Sozol be used during breastfeeding?

Regulatory information states that the active ingredient, Pantoprazole, has been found to pass into breast milk. Official labels state that use during breastfeeding involves weighing the potential benefits against the unknown risk to the infant.


Q: What should I tell my pharmacist about before getting Sozol?

According to general patient guidance, you should inform your pharmacist about all existing medical conditions, especially liver disease or low mineral levels. General guidance suggests disclosing all medications and supplements currently taken, as well as status regarding pregnancy or breastfeeding.


Q: Is there a link between Sozol and mood changes?

The official label does include documented, though rare, neurological and psychiatric adverse effects. While generalized mood changes are not commonly reported, specific rare effects can include dizziness, fatigue, and uncommon cases of depression or hallucinations.


Q: Why do I need a prescription for Sozol?

The requirement for a prescription for certain forms or doses is established by regulatory authorities. This is necessary because the medicine requires professional evaluation to ensure symptoms are not masking a more serious underlying condition and to manage potential risks associated with its long-term use.

How should Sozol be stored and disposed of?

How to Store and Dispose of Sozol

Storage Conditions

Sozol (pantoprazole) tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (or 68 F to 77 F), according to official labeling. It is essential to keep the medicine in its original, tightly closed container and protect it from excess heat and moisture. The product must be strictly kept from freezing to maintain the stability of the delayed-release formulation. All forms of Sozol must be stored out of the reach of children.

Disposal Instructions

Disposal of unused or expired Sozol must follow regulatory guidelines. The preferred method is to use an authorized drug take-back program (such as a local collection site or mail-back envelope). If a take-back program is unavailable, the medicine is not on the FDA's flush list and should be disposed of in the household trash after mixing it with an undesirable substance (like coffee grounds) and placing the mixture in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sozol found in:

A-Z Index: